Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3364-3373

  Aguero, Martin F ^a   Facchinetti, Maria M ^a   Sheleg, Zhanna ^a   Senderowicz, Adrian M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; ISOFLAVONE DERIVATIVE; PHENOXODIOL; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CELL STRUCTURE; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN INDUCTION; STATISTICAL SIGNIFICANCE; WILD TYPE;

EID: 17144381683     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2429     Document Type: Article

References (53)

1. Howe HL, Wingo PA, Thun MJ, et al. Annual Report to the Nation on the Status of Cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
2. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003;7:215-34.
3. Fischer PM. CNIO Cancer Conference: targeted search for anticancer drugs. Expert Opin Investig Drugs 2003;12:1039-44.
4. Frijhoff AF, Conti CJ, Senderowicz AM. Second symposium of novel molecular targets for cancer therapy. Oncologist 2002;7:1-3.
5. Politi PM, Senderowicz AM. First symposium of novel molecular targets for cancer therapy. Oncologist 2001;6:207-12.
6. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anti-Canc Agents 2002;2:691-714.
7. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest 2003;21:744-57.
8. Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 1999;34:12-9.
9. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
10. Alhasan SA, Aranha O, Sarkar FH. Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res 2001;7:4174-81.
11. Akimoto T, Nonaka T, Ishikawa H, et al. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys 2001;50:195-201.
12. Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ. Anticancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci 2003;94:215-20.
13. WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 1998;31:184-91.
14. Takimoto CH, Glover K, Huang X, et al. Phase 1 pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213-21.
15. Miltyk W, Craciunescu CN, Fischer L, et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003;77:875-82.
16. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 2002;76:588-94.
17. Kelly GE, Husband AJ. Flavonoid compounds in the prevention and treatment of prostate cancer. Methods Mol Med 2003;81:377-94.
18. Wilkinson E. Phenoxodiol offers hope for ovarian cancer. Lancet Oncol 2004;5:201.
19. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611-20.
20. Constantinou AI, Husband A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4- hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 2002;22:2581-5.
21. Patel V, Senderowicz AM, Pinto D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-81.
22. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002;62:1401-9.
23. Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res 2004;64:3629-37.
24. Parker B, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
25. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-41.
26. De Siervi A, Marinissen M, Diggs J, Wang XF, Pages G, Senderowicz A. Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. Cancer Res 2004;64:743-50.
27. Kelly G. Interim results of a phase Ib/IIa study of oral phenoxodiol in patients with late-stage, hormone-refractory prostate cancer [abstract]. Proc Am Assoc Cancer Res 2004;45 Suppl 1:103-4.
28. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
29. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17:313-20.
30. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-87.
31. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-8.
32. Taya Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 1997;22:14-7.
33. 1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
34. Elattar TM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res 2000;20:1733-8.
35. Liesveld JL, Abboud CN, Lu C, et al. Flavonoid effects on normal and leukemic cells. Leuk Res 2003;27:517-27.
36. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.
37. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003;283:1-16.
38. Wang CW, Klionsky DJ. The molecular mechanism of autophagy. Mol Med 2003;9:65-76.
39. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96.
40. Sperandio S, Poksay K, De Belle I, et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 2004;11:1066-75.
41. Zong W-X, Ditsworth D, Bauer DE, Wang Z-Q, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272-82.
42. Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004;16:670-8.
43. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-91.
44. 1-phase progression. Genes Dev 1999;13:1501-12.
45. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
46. Senderowicz AM. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. In: Giaccone G, Schilsky RL, Sondel PM, editors. Cancer chemotherapy & biological response modifiers. Oxford (UK): Elsevier Science; 2001.
47. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003;2:S84-95.
48. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
49. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
50. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 1993;366:704-7.
51. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases [see comments]. Nature 1993;366:701-4.
52. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83.
53. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-62.